GlassScriptPhysician profile
Nawaf Murshed
NPI 1619102134
$16,484.09
in general payments reported to CMS, 2019-2025
69 companies · $3,398 in 2025
The $3,398 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,453 · 2020: $1,130 · 2021: $1,771 · 2022: $2,398 · 2023: $2,777 · 2024: $2,557 · 2025: $3,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,917 · Travel and Lodging: $798 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,917.32 |
| Travel and Lodging | $798.33 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,789.00 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $1,503.42 | 2019-2025 | |
| Abbvie INC. | $1,398.24 | 2021-2025 | |
| Biogen, INC. | $1,149.88 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Livanova USA, INC. | $1,091.25 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $582.09 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $491.36 | 2019-2025 | |
| Neurelis, INC. | $479.87 | 2020-2025 | Valtoco |
| Argenx US, INC. | $477.92 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $477.54 | 2019-2025 | Mavenclad |
| Amgen INC. | $464.66 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $459.27 | 2019-2025 | |
| Eisai INC. | $457.09 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $321.45 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Celgene Corporation | $321.42 | 2021-2024 | Zeposia |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nawaf Murshed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.